Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

52 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-12

Study Completion Date

2021-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is Safety, Tolerability and Pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody injection in Healthy Subjects. There are 6 Groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 subjects were included in each of the S2 \~ S6 groups (of which 8 received study drugs and 2 received placebo). Pharmacokinetics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerance, efficacy and immunogenicity for healthy subjects will be evaluated.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Assess the Efficacy, Safety and Tolerability of IRL201104 in Adults With Active Eosinophilic Esophagitis

NCT05084963

Eosinophilic Esophagitis

COMPLETED PHASE2

Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection

NCT04361812

TERMINATED PHASE1

Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome

NCT00017862

Hypereosinophilic Syndrome

COMPLETED PHASE2

A Phase 1, Randomized, Placebo-controlled, Dose-escalation Safety Study of MEDI4212 in Subjects With IgE >= 30 IU/mL

NCT01544348

Allergic Asthma Atopic Dermatitis Allergic Rhinitis +1 more

COMPLETED PHASE1

Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial

NCT05334368

Hypereosinophilic Syndrome

RECRUITING PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a randomized, double-blind, placebo-controlled parallel trial of safety, tolerability and pharmacokinetic of Recombinant anti-IL-5 Humanized Monoclonal Antibody by single subcutaneous injection with six different doses in healthy subjects. There are 6 groups as follows: 0.03mg/kg (S1), 0.2mg/kg (S2), 1.0mg/kg (S3), 3.0mg/kg (S4), 5.0mg/kg (S5) and 7.5mg/kg (S6); and 2 subjects were included in the S1 group (both received study drugs); 10 subjects were included in each of the S2 \~ S6 groups (of which 8 received study drugs and 2 received placebo). In each group, two subjects were sentinels (1 received the study drug and 1 placebo). Pharmacokinetics and Anti-drug antibody (ADA) data will be collected; Drug safety, tolerance, efficacy and immunogenicity for healthy subjects will be evaluated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

610 group

Participants will be administered with 0.03mg/kg, 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg of 610 by subcutaneous injection. Subjects will be followed for 84 days.

Group Type EXPERIMENTAL

610

Intervention Type DRUG

Recombinant anti-IL-5 Humanized Monoclonal Antibody

controll group

Participants will be administered with 0.2mg/kg, 1.0mg/kg, 3.0mg/kg, 5.0mg/kg, 7.5mg/kg placebo once by subcutaneous injection. Subjects will be followed for 84 days.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

610

Recombinant anti-IL-5 Humanized Monoclonal Antibody

Intervention Type DRUG

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Chinese healthy participants, male or female, aged 18 to 55 (including both ends)
* The body mass index (BMI) is in the range of 19.0\~28.0 kg•m-2 (including both ends), and the weight of men is generally not less than 50kg, while the women is generally not less than 45kg
* Male participants and their partners or female participants must agree to take one or more non-drug contraceptives (such as complete abstinence, contraceptive rings, partner ligation, etc.) , and there is no sperm donation or egg donation plan
* Participants should fully understand the purpose, nature, methods and possible adverse reactions of the trial, volunteer to participate in the trial and sign the informed consent
* Participants could communicate well with the researchers and compliance with the trial

Exclusion Criteria

* Those who are allergic to the study drug and any of its excipients. Subjects who have a history of allergy to monoclonal antibodies, and with allergies (multiple drugs and food allergies)
* Subjects who have or are currently suffering from any serious clinical diseases such as circulatory system, endocrine system, nervous system, digestive system, respiratory system, urogenital system, hematology, immunology, psychiatry and metabolic abnormalities or any other that can interfere with the study results
* Those who have undergone surgery within the 3 months prior to the trial that will affect the absorption, distribution, metabolism, and excretion of the drug; or those who have undergone surgery within 4 weeks prior to the trial, or plan to undergo surgery during the study
* Positive for Hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HbcAb), anti- Hepatitis C virus antibodies (HCV), or anti-human immunodeficiency virus (HIV)
* Alcoholics or frequent drinkers within 6 months before the trial, drinking more than 14 units per week (1 unit alcohol ≈360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine), or couldn't prohibit alcohol during the trial or alcohol breath test results greater than 0.0 mg / 100 mL
* Those who smoked more than 5 cigarettes per day during the 3 months before screening, or who cannot stop using any tobacco products during the trial
* Drug abusers or those who have used soft drugs (such as marijuana) within 3 months or took hard drugs (such as cocaine, phencyclidine, etc.) within 1 year before the trial, or have positive drug abuse screening (morphine, methamphetamine , Ketamine, ecstasy, marijuana)
* Has taken any prescription medicine, non-prescription medicine, Chinese herbal medicine or health products (vitamins, cod liver oil, etc.) within 14 days before administration
* Has received any monoclonal antibody drugs within 5 half-lives before administration
* Has a history of vaccination within 4 weeks before dosing, or intend to receive vaccines during the study
* Has parasitic infection at present and within 3 months before dosing
* Was previously enrolled in other clinical trials within 3 months
* Blood donors or subjects who lost a lot of blood (\> 400 mL, except for women's physiological period) or those who received blood transfusion or used blood products within 3 months
* Can't tolerate venipuncture or has a history of halo needles and halo blood
* Has known or suspected pregnancy or lactation
* Abnormal vital signs (SBP \<90 mmHg or ≥140 mmHg, DBP \<55 mmHg or ≥90 mmHg; heart rate \<50 bpm or\> 100 bpm; body temperature (ear temperature) \<35.4℃ or \> 37.7℃) or abnormal ECG (QTcB male ≥450 ms, female ≥460 ms) or physical examination, laboratory examination, and abdominal ultrasound examination are clinically significant (according to the judgment of clinical research doctors)
* Subjects who are unsuited to the study for any reason, judged by the investigators.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes